According to FutureWise analysis the market for methymalonic acidemia in 2023 is US$ 9.64 billion, and is expected to reach US$ 14.48 billion by 2031 at a CAGR of 5.22%.
Metabolic disorders such as methylmalonic acidemia cause the body to have problems breaking down certain proteins and fats. A substance called methylmalonic acid builds up in the blood as a result. The condition is passed down through families. One of several conditions called an "inborn error of metabolism." Symptoms may include lethargy, failure to thrive, recurrent vomiting, acidosis, dehydration, respiratory distress, diminished muscle tone, developmental retardation, seizures, and/or an enlarged liver. In methylmalonic acidemia, the body cannot properly process certain proteins and fats (lipids). Early infancy is usually when methylmalonic acidemia appears and its effects can range from mild to life-threatening. It can cause vomiting, dehydration, weak muscle tone (hypotonia), developmental delay, excessive tiredness (lethargy), and failure to gain weight and grow at the expected rate (failure to thrive). Complications can include feeding difficulties, intellectual disability, chronic kidney disease, and pancreatitis (inflammation of the pancreas). There are some cases in which this disorder can lead to coma or death without treatment. MMA (methylmalonic acidemia) is a type of heterogeneous disorder caused by gene mutations, where the body cannot break down certain proteins and fats, causing methylmalonic acid to build up in the blood or urine. There are genetic defects related to the metabolism of methyl malonyl-coenzyme A (CoA), vitamin B12, or any dietary deficiency that is passed from one generation to the next. Other biochemical abnormalities associated with MMA include low methionine and elevated homocysteine, and children with MMA lack the protein required by their bodies to digest food. Defining methylmalonic acidemia as the inability of the body to breakdown certain proteins and fats, it is a metabolic disorder. The result is a buildup of methylmalonic acid in the blood, which is passed down from generation to generation. In methylmalonic acidemia (MMA), the body is unable to properly break down certain proteins and fats (lipids) because of an inherited condition. Early infancy is usually the time when the disease appears, ranging from mild to life-threatening. It is caused by mutations in the genes MMUT, MMAA, MMAB, MMADHC, and MCEE.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Methymalonic Acidemia Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Methymalonic Acidemia Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.